Literature DB >> 4273095

Mithramycin therapy in Paget's disease.

A S Russell, B C Lentle.   

Abstract

Nine patients with symptomatic Paget's disease were treated with mithramycin in doses of 15 mug/kg/day for 10 days. All but one had considerable symptomatic improvement and, in some, pain relief was dramatic after only a few days. A progressive decrease in serum alkaline phosphatase levels and urinary hydroxyproline excretion was seen at the same time. Bone scans with technetium-99m stannous polyphosphate were performed in six patients and were grossly abnormal in all, showing increased uptake in areas approximately co-extensive with the radiological changes. In five cases improvement in the scans was seen during therapy. In those cases in which the scans had not returned to normal by the end of therapy the improvement continued and was associated with a further decrease in serum alkaline phosphatase levels. We suggest that mithramycin is effective therapy for Paget's disease and, in the dose used, is safe.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4273095      PMCID: PMC1947298     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  18 in total

Review 1.  The cellular basis of metabolic bone disease.

Authors:  H Rasmussen; P Bordier
Journal:  N Engl J Med       Date:  1973-07-05       Impact factor: 91.245

2.  Treatment of Paget's disease with mithramycin: further experiences.

Authors:  W G Ryan; T B Schwartz; G Northrop
Journal:  Semin Drug Treat       Date:  1972

3.  Hypoparathyroidism and Paget's disease: the effect of parathyroid hormone administration.

Authors:  S M Genuth; L Klein
Journal:  J Clin Endocrinol Metab       Date:  1972-11       Impact factor: 5.958

4.  Mithramycin in the treatment of Paget's disease of bone.

Authors:  E G Elias; J T Evans
Journal:  J Bone Joint Surg Am       Date:  1972-12       Impact factor: 5.284

5.  Development of antibodies to porcine calcitonin during treatment of Paget's disease of bone.

Authors:  W J Dube; R S Goldsmith; S B Arnaud; C D Arnaud
Journal:  Mayo Clin Proc       Date:  1973-01       Impact factor: 7.616

6.  Experiences in the treatment of Paget's disease of bone with mithramycin.

Authors:  W G Ryan; T B Schwartz; G Northrop
Journal:  JAMA       Date:  1970-08-17       Impact factor: 56.272

7.  Effects of mithramycin on Paget's disease of bone.

Authors:  W G Ryan; T B Schwartz; C P Perlia
Journal:  Ann Intern Med       Date:  1969-03       Impact factor: 25.391

8.  Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment.

Authors:  R Smith; R G Russell; M C Bishop; C G Woods; M Bishop
Journal:  Q J Med       Date:  1973-04

9.  Mithramycin inhibition of ribonucleic acid synthesis.

Authors:  J W Yarbro; B J Kennedy; C P Barnum
Journal:  Cancer Res       Date:  1966-01       Impact factor: 12.701

10.  Calcitonin resistance: clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins.

Authors:  J G Haddad; J G Caldwell
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

View more
  1 in total

1.  Paget's disease of bone.

Authors:  E S Siris; T P Jacobs; R E Canfield
Journal:  Bull N Y Acad Med       Date:  1980-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.